Search - tctmd.com

Displaying 1 - 2 of 2

Sort: Relevancy | Date

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.